Tuesday was the biggest single-day M&A event in biopharma since the start of 2026. Eli Lilly committed up to $7.8 billion to acquire Centessa Pharmaceuticals and its OX2R agonist pipeline for narcolepsy and sleep-wake disorders, expanding beyond metabolic disease and oncology into neuroscience for the first time at scale. Hours later, Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals at a staggering 140% premium, adding two approved complement-targeting drugs and $689 million in revenue to a company that desperately needs growth as its MS franchise declines. Combined with the Merck/Terns deal, Novartis/Pikavation, the Insilico AI partnership, and the Gilead and Sanofi T-cell engager deals, March 2026 has now produced more than $28 billion in announced M&A value—a pace the industry has not seen in years. The patent cliff is no longer a future concern. It is actively reshaping corporate strategy across the sector in real time.
Top Story: Lilly Pays $7.8B to Enter Sleep Medicine with Centessa
What Happened: Eli Lilly announced a definitive agreement to acquire Centessa Pharmaceuticals for $38 per share in cash at closing plus a contingent value right of up to $9 per share tied to U.S. regulatory approvals, for a total potential value of up to $7.8 billion (~$6.3 billion upfront equity value). The deal represents a 38% premium to Monday’s closing price and a 40.5% premium to the 30-day volume-weighted average price. Close is expected in Q3 2026.
The Science: Targeting the Root Cause of Narcolepsy
Centessa is developing a pipeline of orexin-2 receptor (OX2R) agonists for narcolepsy and excessive daytime sleepiness. To understand why Lilly is paying nearly $8 billion for a Phase 2 program, it helps to understand what narcolepsy actually is at the biological level.
Narcolepsy is caused by the loss of orexin-producing neurons in the brain. Orexin (also called hypocretin) is the neuropeptide that maintains wakefulness and regulates the transitions between sleep and wake states. In narcolepsy type 1, autoimmune destruction of these neurons leads to severe, uncontrollable daytime sleepiness, sudden muscle weakness (cataplexy), and disrupted nighttime sleep. In narcolepsy type 2, the orexin system is dysfunctional without complete neuron loss.
Current treatments—stimulants like modafinil, sodium oxybate (Jazz Pharmaceuticals’ Xyrem/Xywav), and solriamfetol—manage symptoms without addressing the underlying orexin deficiency. They keep patients awake or reduce cataplexy episodes, but they do not restore the neurochemical system that is broken.
OX2R agonists take a fundamentally different approach. By directly activating the orexin-2 receptor, these drugs aim to replace the missing orexin signal rather than compensating for its absence through alternative stimulant pathways. If the mechanism works as the preclinical and early clinical data suggest, OX2R agonists would be the first disease-modifying therapy for narcolepsy—treating the cause rather than managing the consequences.
Why Lilly Is Diversifying Beyond GLP-1
This is Lilly’s fourth major acquisition in approximately 12 months, and it reveals a strategic imperative that extends beyond sleep medicine. Lilly is the most valuable pharmaceutical company on earth, but its market capitalization is built on a narrow foundation. Tirzepatide, orforglipron, and retatrutide are all GLP-1 or GLP-1-adjacent mechanisms. If anything disrupts the obesity thesis—a safety signal, a pricing intervention, a competitive breakthrough—the entire valuation is exposed.
Centessa addresses this concentration risk directly. A potential best-in-class narcolepsy franchise gives Lilly a new therapeutic vertical with its own clinical trajectory, commercial dynamics, and growth profile that is completely independent of metabolic medicine. The OX2R agonist mechanism is distinct from everything else in Lilly’s portfolio.
The CVR Structure: What It Signals About Confidence
The deal’s contingent value right structure is worth parsing. Lilly is paying $38 per share upfront and an additional $9 per share contingent on U.S. regulatory approvals—a total of $47 per share if the drugs get approved. The CVR means Lilly is willing to pay a 23% premium on top of the upfront price for regulatory de-risking. This signals confidence in the science but a desire for milestone alignment on the path to approval. The lead OX2R agonist is in Phase 2, and analysts project blockbuster potential if registrational data confirms the early clinical signal.
Our Pro brief analyzes why the $7.8B Centessa deal is a direct response to GLP-1 concentration risk, how the OX2R mechanism compares to current narcolepsy treatments, and what the CVR structure reveals about Lilly’s regulatory confidence. [Details below.]
What to Watch
Centessa’s Phase 2 data readouts will be the near-term clinical catalyst. The regulatory meeting to discuss registrational pathway design will determine the timeline to a potential NDA. The deal is expected to close in Q3 2026, at which point Lilly will disclose its development plans for the OX2R pipeline. Watch for competitive responses from Jazz Pharmaceuticals, which currently dominates the narcolepsy market with Xywav and Lumryz.
Biogen Pays 140% Premium to Land Apellis
What Happened: Biogen announced a definitive agreement to acquire Apellis Pharmaceuticals for $41 per share in cash plus a CVR of up to $4 per share tied to Syfovre sales milestones. The total upfront value is approximately $5.6 billion, representing a 140% premium to Apellis’s Monday closing price. Close is expected in Q2 2026.
The Assets: Two Approved Drugs and Growing Revenue
Apellis brings two approved complement-targeting therapies. Syfovre (pegcetacoplan for geographic atrophy in age-related macular degeneration) and Empaveli (pegcetacoplan for paroxysmal nocturnal hemoglobinuria) generated $689 million in combined 2025 revenue and are expected to grow at mid-to-high teens through at least 2028.
Syfovre is the commercially larger asset, operating in the geographic atrophy market alongside Apellis’s primary competitor, Iveric Bio’s Izervay (now owned by Astellas). Geographic atrophy—the advanced dry form of AMD—affects approximately 5 million people globally and had no approved treatments until 2023. The market is still in early-stage development, with penetration rates well below potential, providing substantial growth runway.
Why 140% Is the Price of Desperation—and Execution Capability
A 140% premium is not normal. It signals urgency. Biogen’s core MS franchise—built on Tecfidera, Tysabri, and Spinraza—is in structural decline. Leqembi in Alzheimer’s disease has had a slower-than-expected commercial launch. The company needed diversification, and it needed revenue that is growing now, not revenue that might materialize in three to five years.
But the premium also reflects something more specific than revenue acquisition. Biogen is not just buying Apellis’s drugs—it is buying the nephrology commercial team that can support the launch of felzartamab, a CD38 antibody for kidney transplant rejection that Biogen acquired through the $1.8 billion HI-Bio deal in 2024. Apellis’s commercial infrastructure in complement-mediated kidney disease gives Biogen the execution capability it needs to bring felzartamab to market effectively. Without that team, Biogen would need to build nephrology commercial operations from scratch—a process that takes years and carries significant execution risk.
Our Pro brief breaks down what the 140% premium reveals about Biogen’s urgency, the strategic logic of acquiring commercial execution capability alongside approved products, and the integration risks that could make the premium look very different in hindsight. [Details below.]
What to Watch
Syfovre’s quarterly revenue trajectory will be the most scrutinized metric post-close. The CVR tied to Syfovre sales milestones aligns incentives on geographic atrophy uptake, but real-world adoption rates and competition from Izervay will determine whether Biogen gets full value from the premium it paid. The felzartamab launch timeline and early commercial signals in kidney disease will reveal whether the nephrology team acquisition thesis is validated.
Clinical & Research Updates
Novo’s Awiqli: The First Once-Weekly Basal Insulin
What Happened: Novo Nordisk received FDA approval on March 26 for Awiqli (insulin icodec), the first and only once-weekly basal insulin for adults with type 2 diabetes. The approval was overshadowed by the Merck/Terns deal and Maze data that landed the same day, but it deserves attention. This is the first change to basal insulin dosing frequency in more than two decades.
The Data: The ONWARDS Phase 3a program included four randomized, active-controlled trials in approximately 2,680 adults with uncontrolled T2D. Awiqli demonstrated comparable efficacy in HbA1c reduction versus daily basal insulin across all pivotal trials, with safety consistent with the basal insulin class. The fundamental value proposition is simple: Awiqli reduces injections from seven per week to one.
Why This Matters: The convenience parallel to what weekly GLP-1 injections did for that drug class is direct and instructive. Daily basal insulin requires patients to inject at the same time every day—a regimen that creates significant adherence friction in real-world practice. Missed or mistimed doses contribute to suboptimal glycemic control, which drives the long-term complications that make diabetes so expensive to manage.
A once-weekly insulin addresses the behavioral barrier that daily dosing creates. If Awiqli captures even a modest share of the global basal insulin market—which exceeds $15 billion annually—it becomes a meaningful commercial asset. Novo expects to launch via the FlexTouch device in H2 2026. The product is already approved in the EU and 13 additional countries.
The Competitive Angle: Lilly has a competing once-weekly insulin, efsitora alfa, in late-stage development. The weekly basal insulin space is about to become a head-to-head battle between the same two companies fighting for dominance in obesity. Awiqli also previously received a CRL in July 2024 on manufacturing issues—the same pattern as Rocket’s Kresladi—making this another second-attempt approval success.
The March 2026 M&A Scorecard
The acquisition pace this month has been extraordinary. A summary of the major deals:
Lilly/Centessa: $7.8B (narcolepsy/sleep medicine). Merck/Terns: $6.7B (CML hematology). Biogen/Apellis: $5.6B (complement immunology/kidney). Novartis/Pikavation: $3B (PI3Kα breast cancer). Lilly/Insilico: $2.75B (AI drug discovery). Gilead/Ouro: $1.675B (autoimmune T-cell engager). Sanofi/Kali: $1.23B (autoimmune trispecific T-cell engager).
That is more than $28 billion in announced deal value in a single month. The patent cliff—Keytruda in 2028, Humira erosion ongoing, Opdivo and Revlimid pressures mounting—is driving capital deployment at a pace that reflects genuine strategic urgency across the sector’s largest companies.
Strategic Themes
1. Concentration Risk Is Driving Diversification at Record Speed
Lilly’s Centessa deal is the clearest expression of a theme running through every major acquisition this month: companies are spending aggressively to reduce franchise concentration risk. Lilly’s metabolic dominance is extraordinary, but the GLP-1 dependence creates a vulnerability that no management team can ignore. Adding a neuroscience vertical with an independent growth trajectory is a direct hedge against the scenario where metabolic medicine faces unexpected headwinds. The same logic applies to Merck (Keytruda cliff), Biogen (MS decline), and Novartis (Kisqali pipeline depth).
2. Premiums Are Rising Because the Alternatives Are Worse
Biogen’s 140% premium for Apellis, Merck’s 42% VWAP premium for Terns, Lilly’s 38% premium for Centessa—the willingness to pay up for assets reflects a buyer’s market that is paradoxically expensive. Companies with looming patent cliffs or declining franchises are competing against each other for a limited pool of commercial-stage or late-clinical assets. The cost of not doing a deal—watching revenue erode without replacement—exceeds the cost of overpaying for assets that might not fully deliver. This dynamic will persist as long as the patent cliff timeline remains compressed.
3. $28B in March M&A Signals a Structural Shift in How Pharma Sources Growth
The pace of dealmaking in March 2026 is not cyclical—it is structural. The industry’s largest companies are collectively acknowledging that internal R&D alone cannot replace the revenue that is about to evaporate from patent expirations. External innovation, purchased at premium prices, has become the primary growth strategy for big pharma. The implications for biotech valuations are significant: any clinical-stage company with differentiated assets in high-priority therapeutic areas is a potential acquisition target, and the premiums being paid establish new floor prices for deal negotiations.
4. The Metabolic Arms Race Continues in Parallel
While the M&A machine dominates headlines, the metabolic competitive landscape continues to evolve. Lilly’s orforglipron decision arrives in 9 days. Novo’s Wegovy HD is rolling out across pharmacies this month. Novo’s Awiqli quietly adds another dimension to the diabetes portfolio. And retatrutide obesity data is expected by mid-year. The simultaneous progression of M&A diversification and metabolic franchise expansion illustrates Lilly’s ability to execute on multiple strategic fronts simultaneously—a capability that increasingly separates it from competitors focused on one challenge at a time.
Frequently Asked Questions
Why is Lilly paying $7.8B for a Phase 2 narcolepsy program?
Lilly’s valuation is heavily indexed to GLP-1 outcomes. A narcolepsy franchise built on OX2R agonists gives the company a new therapeutic vertical completely independent of metabolic medicine, reducing concentration risk. The OX2R mechanism targets the root cause of narcolepsy (orexin deficiency) rather than managing symptoms, which current treatments do. The CVR structure ($38 upfront + $9 on FDA approvals) shows Lilly is confident in the science but wants milestone alignment on the regulatory path.
What does the 140% premium tell us about Biogen’s position?
A 140% premium signals urgency. Biogen’s MS franchise is in structural decline, and Leqembi’s Alzheimer’s launch has been slower than expected. Apellis provides $689 million in growing revenue, two approved drugs, and a nephrology commercial team that can support the felzartamab kidney disease launch. Biogen paid for both products and execution capability it does not have internally.
What is Awiqli, and why does it matter?
Awiqli (insulin icodec) is the first once-weekly basal insulin, approved March 26. It reduces injections from seven per week to one for type 2 diabetes patients. The basal insulin market exceeds $15 billion globally, and the convenience advantage mirrors what weekly GLP-1 injections did for that drug class. Novo launches in H2 2026; Lilly’s competing weekly insulin (efsitora alfa) is in late-stage development.
How much M&A has been announced in March 2026?
More than $28 billion across seven major transactions: Lilly/Centessa ($7.8B), Merck/Terns ($6.7B), Biogen/Apellis ($5.6B), Novartis/Pikavation ($3B), Lilly/Insilico ($2.75B), Gilead/Ouro ($1.675B), and Sanofi/Kali ($1.23B). The pace reflects strategic urgency driven by looming patent cliffs and franchise concentration risk across the industry’s largest companies.
What is driving the record M&A pace?
Patent cliffs are the primary catalyst. Keytruda (Merck) loses core protection in 2028, Humira erosion is ongoing, and multiple other blockbusters face biosimilar competition within the next three to four years. Companies cannot replace the revenue at risk through internal R&D alone, forcing aggressive external acquisition of clinical-stage and commercial-stage assets.
How does the Centessa deal compare to Lilly’s other recent acquisitions?
Centessa is Lilly’s fourth major deal in roughly 12 months, following Morphic Therapeutic (GI), the Insilico AI partnership, and earlier pipeline acquisitions. The Centessa deal is the largest and represents the most significant therapeutic diversification—entering neuroscience for the first time at scale. The pattern shows Lilly systematically expanding beyond its metabolic core while continuing to build its GLP-1 franchise.
What is the competitive landscape for narcolepsy treatments?
Jazz Pharmaceuticals dominates narcolepsy with Xywav and Lumryz (sodium oxybate products) plus solriamfetol (Sunosi). These are symptom-management therapies that do not address the underlying orexin deficiency. If Centessa’s OX2R agonist demonstrates disease-modifying efficacy in registrational trials, it would represent a mechanistic leap beyond any currently available treatment and threaten Jazz’s market position directly.
What should investors watch with orforglipron in 9 days?
The April 10 target action date would cap an extraordinary stretch for Lilly: the Insilico AI deal, the Centessa acquisition, and a potentially transformative oral GLP-1 approval all within two weeks. Key factors include label scope, the $149 LillyDirect pricing commitment, and how the approval interacts with the White House drug pricing legislative push. Lilly has stockpiled $1.5 billion worth of orforglipron for immediate launch readiness.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Lilly’s Diversification Imperative. We analyze why paying $7.8B for a Phase 2 narcolepsy asset is a direct response to GLP-1 concentration risk, map the OX2R competitive landscape against Jazz Pharmaceuticals’ established franchise, and model the CVR economics under approval and non-approval scenarios.
Biogen’s 140% Premium — Desperation or Discipline? We break down what the premium reveals about Biogen’s strategic urgency, why the nephrology team acquisition is as important as the approved products, and the integration risks that could make the deal look very different depending on Syfovre trajectory and felzartamab execution.
March 2026 M&A Tally: $28B and Counting. We compile the full month’s deal activity, analyze the strategic patterns driving capital deployment, and assess what the premium compression trend means for biotech companies currently in acquirer sightlines.
Plus: Orforglipron 9-day countdown, Wegovy HD early launch signals, Awiqli competitive framing versus Lilly’s efsitora alfa, and the updated catalyst calendar through mid-2026.
BioMed Nexus Announcement: Industry Directory Is Live
The BioMed Nexus Industry Directory is now the most comprehensive categorized database of companies across biotech, pharma, and life sciences, with 2,100+ companies listed across 14 live directories. Whether you’re sourcing CROs, mapping the AI drug discovery landscape, evaluating CDMOs, or looking for regulatory counsel, it’s all in one place.
Companies can claim a free listing or upgrade to a featured profile. Learn about our Data Partner program →
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
